Clinical Trial Update: Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating tislelizumab with nab-paclitaxel and gemcitabine for recurrent pancreatic cancer is being investigated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Changhai Hospital | Conditions: Recurrent Pancreatic Cancer | Phase 2 | Status: UNKNOWN